Solving the Puzzle of Immune Tolerance for β-Cell Replacement Therapy for Type 1 Diabetes
Open accessAbstract
Type 1 diabetes mellitus results from autoimmune destruction of pancreatic β cells. Insulin treatment is often inadequate in preventing devastating complications. Replacing β cells using stem cell-derived islets while fostering immune tolerance, exemplified in Yoshihara et al., holds the promise of a curative therapy for this disease.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The main cause of rejection in allogeneic transplantation is T-cell recognition of human leukocyte antigens (HLAs).
“The main cause of rejection in allogeneic transplantation is T-cell recognition of human leukocyte antigens (HLAs).”
From Developments in stem cell-derived islet replacement therapy for treating type 1 diabetes (2023) · cites this paper as [117]
No passage from our copy matched the claim, and searches for allogeneic transplantation, HLA, T cells, and rejection returned no passages. The available text therefore does not establish whether the paper identifies T-cell recognition of HLAs as the main cause of rejection. (LLM, conf=0.70)
Experimental — accuracy not yet measuredHLA class I molecules A, B, and C are present on all nucleated cells and present antigens to CD8+ cytotoxic T-cells, while HLA class II proteins activate CD4+ helper T-cells.
“The HLA class I molecules A, B, and C are present on all nucleated cells and present antigens to CD8+ cytotoxic T-cells, while HLA class II proteins activate CD4+ helper T-cells.”
From Developments in stem cell-derived islet replacement therapy for treating type 1 diabetes (2023) · cites this paper as [117]
No passage from our copy matched the claim. Searches for HLA, MHC class I, CD8 T cells, and CD4 T cells returned no passages, so the copy does not establish the stated distribution or functions of HLA class I and II molecules. (LLM, conf=0.72)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Kroon, E., Martinson, L. A., Kadoya, K., Bang, A. G., Kelly, O. G., Eliazer, S., Young, H., Richardson, M., Smart, N. G., Cunningham, J., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1393 · Cited by 1,843 · see citing works
MYC regulates the antitumor immune response through CD47 and PD-L1
Casey, S. C., Tong, L., Li, Y., Do, R., Walz, S., Fitzgerald, K. N., Gouw, A. M., Baylot, V., Gütgemann, I., Eilers, M., et al. (2016) · Science · doi:10.1126/science.aac9935 · Cited by 1,403 · see citing works
An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes
Herold, K. C., Bundy, B. N., Long, S. A., Bluestone, J. A., DiMeglio, L. A., Dufort, M. J., Gitelman, S. E., Gottlieb, P. A., Krischer, J. P., Linsley, P. S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1902226 · Cited by 1,189 · see citing works
Self-citationTargeting the cytoskeleton to direct pancreatic differentiation of human pluripotent stem cells
Hogrebe, N. J., Augsornworawat, P., Maxwell, K. G., Velazco-Cruz, L., & Millman, J. R. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0430-6 · Cited by 373 · see citing works
Immune-evasive human islet-like organoids ameliorate diabetes
Yoshihara, E., O’Connor, C., Gasser, E., Wei, Z., Oh, T. G., Tseng, T. W., Wang, D., Cayabyab, F., Dai, Y., Yu, R. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2631-z · Cited by 333 · see citing works
Immune checkpoint inhibitor diabetes mellitus: a novel form of autoimmune diabetes
Quandt, Z., Young, A., & Anderson, M. S. (2020) · Clinical & Experimental Immunology · doi:10.1111/cei.13424 · Cited by 186 · see citing works
Regulatory T-cell therapy for autoimmune and autoinflammatory diseases: The next frontier
Esensten, J. H., Müller, Y. D., Bluestone, J. A., & Tang, Q. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.10.015 · Cited by 160 · see citing works
Self-citationAdvances Toward Engineering Functionally Mature Human Pluripotent Stem Cell-Derived β Cells
Velazco-Cruz, L., Goedegebuure, M. M., & Millman, J. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00786 · Cited by 62 · see citing works
Induction of Allograft Tolerance by Monoclonal CD3 Antibodies: A Matter of Timing
You, S., Zuber, J., Kuhn, C., Baas, M. C., Valette, F., Sauvaget, V., Sarnacki, S., Sawitzki, B., Bach, J., Volk, H., et al. (2012) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2012.04213.x · Cited by 60 · see citing works
Mahr, B., Granofszky, N., Muckenhuber, M., & Wekerle, T. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01762 · Cited by 44 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Developments in stem cell-derived islet replacement therapy for treating type 1 diabetes
Hogrebe, N. J., Ishahak, M., & Millman, J. R. (2023) · Cell Stem Cell · doi:10.1016/j.stem.2023.04.002 · Cited by 210 · see citing works
Engineering islets from stem cells for advanced therapies of diabetes
Siehler, J., Blöchinger, A. K., Meier, M., & Lickert, H. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00262-w · Cited by 125 · see citing works
The promise of stem cell-derived islet replacement therapy
Melton, D. (2021) · Diabetologia · doi:10.1007/s00125-020-05367-2 · Cited by 96 · see citing works
Krentz, N. A. J., Shea, L. D., Huising, M. O., & Shaw, J. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00170-4 · Cited by 37 · see citing works
Pignatelli, C., Campo, F., Neroni, A., Piemonti, L., & Citro, A. (2022) · Transplant International · doi:10.3389/ti.2022.10555 · Cited by 25 · see citing works
Tissue engineering of decellularized pancreas scaffolds for regenerative medicine in diabetes
Lim, L. Y., Ding, S. S. L., Muthukumaran, P., Teoh, S. H., Koh, Y., & Teo, A. K. K. (2022) · Acta Biomaterialia · doi:10.1016/j.actbio.2022.11.032 · Cited by 23 · see citing works
Chen, S., Wang, W., Shen, L., Liu, H.-F., Luo, J., Ren, Y., Cui, S., Ye, Y., Shi, G., Cheng, F.-Y., et al. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2024.122947 · Cited by 20 · see citing works
The progress of pluripotent stem cell-derived pancreatic β-cells regeneration for diabetic therapy
Wang, X., Gao, M., Wang, Y.-L., & Zhang, Y.-C. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.927324 · Cited by 22 · see citing works
Stabler, C. L., & Russ, H. A. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.10.011 · Cited by 15 · see citing works
Transforming type 1 diabetes: the next wave of innovation
Drucker, D. J. (2021) · Diabetologia · doi:10.1007/s00125-021-05396-5 · Cited by 14 · see citing works
Cobb, J., Rawson, J., Gonzalez, N., Singer, M., KANDEEL, F. R., & Husseiny, M. I. (2024) · Vaccines · doi:10.3390/vaccines12030276 · Cited by 9 · see citing works
Clinical translational research on stem cell products: prospects and challenges
Chen, S., ZHANG, L., Ren, Y., Bai, X., Wei, X., Chai, M., 崔苏甦, Zhao, X., & Deng, H. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02582-y · Cited by 14 · see citing works
Luo, J., Pei, S.-Y., Ai, Z.-Y., Rao, R., Yang, Z.-Y., Guo, X., Ai, Z.-Y., Fan, L., & Zou, F. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04082-1
Bioengineered Vascularized Insulin Producing Endocrine Tissues
Campo, F., Neroni, A., Pignatelli, C., Bignard, J., Berishvili, E., Piemonti, L., & Citro, A. (2023) · Springer eBooks · doi:10.1007/978-3-031-41943-0_8
Stem Cell–Derived Islet Therapy for Type 1 Diabetes
Barsby, T., Balboa, D., & Otonkoski, T. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-11985-9.00025-1
In vitro generation of regulatory T cells: A challenging tool for studying immune aging in humans
Muller, L., Bleher, J., Weinberger, B., & Rocamora‐Reverte, L. (2026) · FEBS Open Bio · doi:10.1002/2211-5463.70349
- Authors
- Bluestone, J. A., & Tang, Q.
- Affiliations
- University of California, San Francisco (US)
- Corresponding author
- Bluestone, Jeffrey A.
- Tang, Qizhi
- Venue
- Cell Stem Cell
- Publisher
- Elsevier BV
- Published
- 2020-10
- Volume
- 27
- Issue
- 4
- Pages
- 505-507
- ISSN
- 1875-9777 (ISSN-L)
- 1934-5909
- OpenAlex
- W3091596737
- Cited by
- 16
- References
- 10
- Citations by year
- 2026: 4 · 2024: 2 · 2023: 3 · 2022: 3 · 2021: 4
- FWCI
- 2.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cell stem cell (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Pancreatic function and diabetes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- type 1 diabetes, immune tolerance, beta cell replacement therapy, stem cell-derived islets, islet transplantation
- MeSH terms
- Diabetes Mellitus, Type 1, Humans, Immune Tolerance, Islets of Langerhans, Organoids, Insulin-Secreting Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
